ONWARD Medical secures €40 million

ONWARD Medical has successfully raised more than €40 million in a capital increase, marking a significant milestone in its mission to restore movement and independence in people with spinal cord injuries.

The financing round includes a €25 million investment from EQT Life Sciences, alongside strong support from leading institutional and sector-specialist investors. This new funding extends the company’s financial runway into early 2028 and will support the continued development and commercialization of its innovative neurostimulation therapies.

At the heart of ONWARD Medical’s technology lies a remarkable scientific journey that began in Lausanne, at CHUV (Vaud University Hospital) and UNIL (University of Lausanne). The company’s proprietary ARC Therapy is built on pioneering research conducted by Grégoire Courtine, Jocelyne Bloch, and Vincent Delattre. Their work demonstrated that targeted electrical stimulation of the spinal cord can help restore voluntary movement in individuals with paralysis—an achievement that has reshaped the field of neurorehabilitation.

Today, ONWARD Medical is translating this research into clinical and commercial solutions. Its ARC-EX® system is already cleared for use in the United States and Europe, while the implantable ARC-IM® platform is currently undergoing clinical evaluation, including applications to address blood pressure instability in spinal cord injury patients.

The newly raised capital will be used to accelerate product development, expand commercial activities across key markets, and further validate the company’s technologies through clinical studies and regulatory pathways.

This milestone underscores not only the rapid progress of ONWARD Medical as a commercial-stage company, but also the global impact of Swiss research and innovation—originating from Lausanne and now transforming lives worldwide.

➡️ Source: Press Release | 📸 ©ONWARD Medical